Key result
SGLT2i initiation in HFrEF is linked to an ~18% NT-proBNP reduction and coordinated biventricular improvements.
Why the study?
While SGLT2 inhibitors benefit left ventricular recovery in HFrEF, their rapid effects on right ventricular function remain poorly characterized.
Does SGLT2 inhibitor initiation improve biventricular function and NT-proBNP levels in adults with HFrEF?
Observational (n=50)
Does SGLT2 inhibitor initiation improve biventricular function and NT-proBNP levels in adults with HFrEF?
Absolute Event Rate: 913.5% vs 1116.5%
SGLT2 inhibitor initiation in HFrEF is associated with early biventricular improvements and NT-proBNP reduction at 3 months, with baseline TAPSE/PASP ratio predicting RV recovery.
Early RV changes with SGLT2 inhibitors in HFrEF may occur within 3 months; leaves open effects on outcomes and need for randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hammad et al. (2026) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=50). SGLT2 inhibitor was evaluated on NT-proBNP levels. SGLT2 inhibitor initiation in HFrEF patients was associated with a decrease in NT-proBNP levels from 1116.5 to 913.5 pg/mL and coordinated biventricular improvements within 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: